Cher M L, Chew K, Rosenau W, Carroll P R
Department of Urology, University of California School of Medicine, San Francisco.
Prostate. 1995 Feb;26(2):87-93. doi: 10.1002/pros.2990260205.
Prostatic carcinomas vary in their biological potential, even when stratified by grade and stage. Measurement of cellular proliferation by various methods has been shown to correlate with outcome for several human cancers, including prostatic carcinoma. Uptake of bromodeoxyuridine (BrdUrd), a thymidine analogue, has been accepted as a measure of cellular proliferative rate. However, the technique is somewhat complex, requiring incubation with fresh tissue. We compared cellular proliferation as measured by BrdUrd uptake with two more simple immunohistochemical methods in 44 prostatic adenocarcinoma specimens and correlated the results with standard clinical parameters. The tissue was obtained via needle biopsy, channel transurethral resection, and radical prostatectomy. Specimens were incubated in vitro with BrdUrd and then fixed and paraffin embedded. Sections were immunohistochemically stained with antibodies to BrdUrd, proliferating cell nuclear antigen (PCNA), and Ki-67. At least 1,000 cells were scored, and a labeling index (LI) was calculated (number of positive cells/total number of cells). The mean LI determined by all three indices was low (BrdUrd = 3.0, PCNA = 7.0, Ki-67 = 3.4), consistent with the knowledge that prostatic tumors grow slowly. In 36 patients who had not been treated at the time of analysis, the LI as determined by all three methods correlated well with clinical stage and pathological grade. Furthermore, the LIs discriminated between those with tumor confined to the prostate and those with extension to the seminal vesicles, lymph nodes, or bone (P = 0.003, 0.004, 0.008 for BrdUrd, PCNA, and Ki-67, respectively). The LIs for PCNA and Ki-67 correlated well with that for BrdUrd (r = 0.84; r = 0.85), while the LIs for Ki-67 and PCNA correlated slightly less well with each other (r = 0.78). PCNA and Ki-67 expression appear to reflect essentially the same biological process as BrdUrd uptake. Either can substitute for BrdUrd as a measure of cellular proliferation, and Ki-67 seems to offer the fewest technical problems.
前列腺癌的生物学潜能各不相同,即便按分级和分期进行分层也是如此。通过各种方法测量细胞增殖已被证明与包括前列腺癌在内的多种人类癌症的预后相关。溴脱氧尿苷(BrdUrd),一种胸腺嘧啶类似物的摄取,已被公认为细胞增殖率的一种度量方法。然而,该技术 somewhat complex,需要与新鲜组织一起孵育。我们在44例前列腺腺癌标本中,将通过BrdUrd摄取测量的细胞增殖与另外两种更简单的免疫组织化学方法进行了比较,并将结果与标准临床参数相关联。组织通过针吸活检、经尿道通道切除术和根治性前列腺切除术获取。标本在体外与BrdUrd一起孵育,然后固定并石蜡包埋。切片用抗BrdUrd、增殖细胞核抗原(PCNA)和Ki-67的抗体进行免疫组织化学染色。对至少1000个细胞进行评分,并计算标记指数(LI)(阳性细胞数/细胞总数)。由所有三种指数确定的平均LI较低(BrdUrd = 3.0,PCNA = 7.0,Ki-67 = 3.4),这与前列腺肿瘤生长缓慢的认识一致。在分析时未接受治疗的36例患者中,所有三种方法确定的LI与临床分期和病理分级密切相关。此外,LIs区分了肿瘤局限于前列腺的患者和肿瘤已扩展至精囊、淋巴结或骨骼的患者(BrdUrd、PCNA和Ki-67的P值分别为0.003、0.004和0.008)。PCNA和Ki-67的LI与BrdUrd的LI密切相关(r = 0.84;r = 0.85),而Ki-67和PCNA的LI彼此之间的相关性略低(r = 0.78)。PCNA和Ki-67的表达似乎与BrdUrd摄取反映的基本是相同的生物学过程。两者都可以替代BrdUrd作为细胞增殖的一种度量方法,并且Ki-67似乎技术问题最少。